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RNA profiling has emerged as a powerful tool to investigate the biomarker potential of human 
biofluids. However, despite enormous interest in extracellular nucleic acids, RNA sequencing methods 
to quantify the total RNA content outside cells are rare. Here, we evaluate the performance of the 
SMARTer Stranded Total RNA-Seq method in human platelet-rich plasma, platelet-free plasma, urine, 
conditioned medium, and extracellular vesicles (EVs) from these biofluids. We found the method to 
be accurate, precise, compatible with low-input volumes and able to quantify a few thousand genes. 
We picked up distinct classes of RNA molecules, including mRNA, lncRNA, circRNA, miscRNA and 
pseudogenes. Notably, the read distribution and gene content drastically differ among biofluids. In 
conclusion, we are the first to show that the SMARTer method can be used for unbiased unraveling of 
the complete transcriptome of a wide range of biofluids and their extracellular vesicles.
All human biofluids contain a multitude of extracellular nucleic acids, harboring a wealth of information about 
health and disease status. In addition to established non-invasive prenatal testing of fetal nucleic acids in mater-
nal plasma1, liquid biopsies have emerged as a novel powerful tool in the battle against cancer2. Although in the 
past most attention was given to circulating DNA, its more dynamic derivate extracellular RNA may provide 
additional layers of information. However, RNA sequencing in biofluids is technically challenging. Low input 
amounts, large dynamic range, and (partial) degradation of RNA hamper straightforward quantification. While 
sequencing of small RNAs3 and targeted or capture sequencing of longer RNAs4 proved to be successful, studies 
using total RNA sequencing on biofluids are rare. To date, only a few whole transcriptome profiling attempts were 
made on urine, plasma or extracellular vesicles5–9, quantifying both polyadenylated and non-polyadenylated RNA 
transcripts (Table 1). However, all these methods suffer from one or more limitations such as short fragment 
length, low number of quantified genes or a high level of ribosomal RNA contamination. The majority of these 
methods lack a thorough assessment of data quality under the form of technical repeatability and quantitative 
accuracy.
The advantages of total RNA sequencing are plentiful. Indeed, detection is not limited to a set of pre-defined 
targets, nor to (3′ ends of) polyadenylated RNAs. Next to polyadenylated mRNAs, various other RNA biotypes 
including circular RNAs, histone RNAs, and a sizable fraction of long non-coding RNAs can be distinguished. 
In addition, the study of posttranscriptional regulation is possible by comparing exonic and intronic reads10. 
Altogether, this generates a much more comprehensive view of the transcriptome.
Here we aimed to assess the performance of a strand-specific total RNA library preparation method for dif-
ferent types of biofluids and derived extracellular vesicles (EVs). We applied the method on platelet-rich plasma, 
platelet-free plasma, urine and conditioned medium from human healthy donors, cancer patients or cancer cells 
grown in vitro. More specifically, the SMARTer Stranded Total RNA-Seq Kit – Pico Input Mammalian, including a 
ribosomal RNA depletion step at the cDNA level, was extensively evaluated. We found the method to be accurate 
1Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. 2Cancer 
Research Institute Ghent, Ghent, Belgium. 3Department of Dermatology, Ghent University Hospital, Ghent, Belgium. 
4Biogazelle, Zwijnaarde, Belgium. 5Laboratory of Experimental Cancer Research, Department of Human Structure 
and Repair, Ghent University, Ghent, Belgium. 6Department of Urology, Ghent University Hospital, Ghent, Belgium. 
7These authors contributed equally: Celine Everaert and Hetty Helsmoortel. *email: jo.vandesompele@ugent.be
open
2Scientific RepoRtS |         (2019) 9:17574  | https://doi.org/10.1038/s41598-019-53892-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
and precise. Low-input volumes are technically feasible and the method allows the detection of several thousand 
genes of different classes.
Results
Read distribution drastically differs among biofluids. In a first experiment (Fig. 1A), we sequenced 
platelet-rich plasma (PRP) and platelet-free plasma (PFP) from two different healthy donors. We collected blood 
in EDTA tubes, hence the ‘e’ in front of ePRP and ePFP throughout the manuscript. From each plasma fraction, 
two technical RNA extraction replicates were performed, resulting in four sequenced samples per donor. Because 
of the low input, between 53.0% and 88.2% of the reads were PCR duplicates (Sup Fig. 1). PCR duplicates arise 
when multiple PCR products from the same original template molecule bind to the sequencing flow cell. For 
better quantitative accuracy, we removed the duplicates for further analysis. The variation in PCR duplicate levels 
between plasma fractions is related to the amount and quality of input RNA. As we will illustrate below, ePRP has 
a higher RNA input concentration, which explains the lower number of duplicate reads compared to ePFP. After 
duplicate removal we mapped the remaining (deduplicated) reads to the reference genome (Fig. 2A). Four catego-
ries of reads can be distinguished here: uniquely mapping reads, multi-mapped reads aligning to several genomic 
positions, reads that are too short to map, and unmapped reads. The number of unmapped and multi-mapped 
reads was similar between plasma with and without platelets. However, ePFP samples contain much more reads 
that are too short to map. As a consequence, ePRP contains approximately twice as many uniquely mapped reads, 
possibly the result of more intact RNA in platelets. However, when only considering these unique reads, more 
than 75% of them derived from mitochondrial RNA (mtRNA) in ePRP (Fig. 2B). In contrast, ePFP contains at 
least three times less mtRNA and considerably more reads mapping to nuclear DNA. Finally, also the distribution 
between exonic, intronic and intergenic reads differs between platelet-rich and platelet-free plasma (Fig. 2C).
In the second experiment (Fig. 1B), we sequenced conditioned medium from breast cancer cells (CM), 
platelet-free plasma from a third healthy donor collected in a citrate blood collection tube (cPFP) and urine from 
a prostate cancer patient. In addition, we purified EVs from these three fluids and performed extensive quality 
control using western blot, electron microscopy and nanoparticle tracking analysis (Sup Fig. 2). We sequenced 
the EV samples together with their fluids of origin. For this experiment, two technical replicates were introduced 
at the level of library preparation for each condition, resulting in 12 libraries. Because only one biological sample 
of each biofluid was included in this experiment, we should be cautious when generalizing differences among 
biofluids. With the exception of plasma, the number of PCR duplicates is lower in EVs compared to their paren-
tal biofluid (Sup Fig. 1). As mentioned earlier, the levels of PCR duplicates are typically lower in samples with 
higher input quality and concentration. But, as we will see in the next paragraph, RNA input amounts in EVs are 
not higher compared to their fluid of origin. Other explanations, at least in part, could be the protective effect 
lipid bilayers have on the quality of their RNA cargo and the wide differences in RNA content. Interestingly, also 
mapping rates can differ substantially among biofluids and/or their EVs (Fig. 2A). In our setup for instance, the 
fraction of unique reads ranges from 7.69% in cPFP EVs to 90.2% in EVs isolated from conditioned medium. 
When looking at the mapping properties of the unique reads, almost all samples mainly contain reads that map 
to nuclear DNA (Fig. 2B). Only platelet-free plasma contains 25.8% mitochondrial RNA, comparable to the per-
centages that were generated in the healthy donors of the first experiment. Lastly, most reads mapping to nuclear 
DNA are exonic. The only exception here are cPFP EVs that contain a larger fraction of intronic and intergenic 
reads (Fig. 2C). While the platelet-free plasma samples in the first and second experiment seem very similar, 
small differences may be introduced by blood collection tube (EDTA vs. citrate) and/or the use of distinct donors. 
Indeed, also in the first experiment the read distribution was to some extent donor dependent.
We subsequently investigated two other technical characteristics of our biofluid total RNA seq method: 
the level of strandedness and the inner distance between paired-end reads. In general, the method generates 
strand-specific sequencing reads in all the biofluids we assessed (Sup Fig. 3). The cDNA fragment sizes in the 
reference method
library prep
sample types strandedness contaminants
biotypes
small 
RNA
total 
RNA mRNA lncRNA microRNA circRNA
Li et al., 2014 Ion Total RNA-seq v2 (Thermofisher) + −
EVs from serum and 
urine stranded 2–50% rRNA + − + −
Qin et al., 2015 TGIRT-seq − + plasma (1 mL) stranded 0.9–6.3% rRNA + + + −
Savelyeva et al., 
2017
SOLiD sequencing 
technology − +
blood, plasma, EVs 
from plasma NA 4–33% rRNA + + + −
Amorim et al., 
2017
Ion Total RNA-seq v2 
(Thermofisher) + − EVs from plasma stranded NA + + + −
Giraldez et al., 
2019 Akat et 
al., 2019
phospho-RNA-seq + − plasma, bone marrow NA
high YRNA and 
rRNA content 
(percentage not 
reported)
+ + + −
Zhou et al., 
2019 SILVER-seq − + serum (droplet) NA + + + −
this study SMARTer-seq − +
plasma, urine, 
conditioned medium 
(200 µl) and EVs
stranded
mitochondrial rRNA 
depending on sample 
type
+ + − +
Table 1. Comparison of RNA-seq methods to study biofluids and extracellular vesicles.
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library range from 70 to 400 nucleotides, with a peak around 90 nucleotides for the plasma samples and around 
180–190 nucleotides for the other samples. Notably, the plasma samples and derived EVs present with the shortest 
fragment length (Sup Fig. 4). In conclusion, we show for the first time that the SMARTer Stranded Total RNA-Seq 
method works in different human biofluids and their respective EVs. The method generates reproducible read 
distribution results for technical replicates, both at the RNA isolation and library preparation level. The results 
clearly differ according to biofluid sample type.
Spike-in RNA enables relative RNA quantification and fold change trueness assessment. In 
order to assess the quantitative aspect of the total RNA sequencing method, we added an ERCC RNA spike-in 
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Figure 1. Schematic overview of the different experiments.
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mix to all RNA samples prior to library preparation in the experiments above. The addition of spike-in RNA is 
effective as processing control when working with challenging and low input material, and can be used to normal-
ize sequencing reads or calculate input RNA amounts. In addition, the correlation values between the expected 
and observed relative quantities of the spikes can be calculated. The high correlation in our experiments indicate 
excellent recovery of the ERCC spike-in mix during the entire library preparation and sequencing workflow in all 
samples but the conditioned medium (Sup Fig. 5).
As there is an inverse relationship between the number of spike-in RNA reads and the number of endogenous 
RNA reads, the ratio between the sum of the reads consumed by the endogenous transcripts and the total number 
of spike-in reads is a relative measure for the RNA concentration of the various samples. When adding the same 
amount of ERCC RNA to all samples, a higher ratio is indicative of more endogenous RNA. We found the highest 
RNA extraction concentration in conditioned medium, and the lowest in plasma EVs (Sup Fig. 6). Of note, not all 
starting volumes before EV purifications or other handling were equal. For instance, in our urine experiment we 
compare RNA extracted from 200 uL whole urine with RNA isolated from EVs that were present in 45 mL whole 
urine as starting material. Therefore, we corrected the endogenous:ERCC ratios for the original input volumes. 
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Figure 2. Read distribution of all libraries differs among samples. (A) Percentage of reads assigned as too 
short to map, unique- or multi-mapping quantified with STAR. B) Percentage of reads derived from nuclear 
RNA, mitochondrial RNA and ribosomal RNA per sample quantified with STAR. (B) Percentage of the reads 
originating from nuclear chromosomes derived from exonic, intronic and intergenic regions per sample 
quantified with STAR.
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This provides us information about the relative amount of RNA present per milliliter biofluid (Fig. 3A). While 
ePRP, conditioned medium and urine have very similar RNA concentrations, ePFP and cPFP contain approxi-
mately 17 times less RNA. In addition, EVs from condition medium hold 2763 times less RNA compared to their 
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Figure 3. Spike-in RNA based assessment of relative RNA concentration and trueness. (A) Relative RNA 
concentration estimation. (B) Relationship between expected and observed log2 fold changes shows an overall 
good correlation. (C) The log2 fold change differences are higher in spikes with low counts. (D) Cumulative 
distributions of log2 fold change differences demonstrate good concordance between expected and observed 
differences.
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fluid of origin, plasma EVs 616 times less and urine EVs 7.6 times less. Given that only one biological sample was 
included in this experiment, further studies warranted to validate these differences in RNA concentration.
In a separate experiment, we added two different spike-in mixes in varying amounts to five identical ePFP 
samples from a fourth healthy donor. Sequin spikes (n = 78) and ERCC spikes (n = 92) were diluted in opposite 
order by a factor 1.41 in the five derivative samples. In this way, a biologically relevant 4-fold dynamic range 
for both Sequin and ERCC spikes was covered (Fig. 1C). The aim of this experiment was to assess the method’s 
trueness by comparing expected and observed fold changes of the 170 sequenced spike-in RNAs. Of note, both 
Sequin and ERCC spike mixes consist of multiple RNA molecules present in varying concentrations. Based on 
pre-experiments, we made sure that we added the spikes in such amounts that the number of reads going to the 
spikes with the highest concentration (for both the Sequin and ERCC panel) was lower than the number of reads 
going to the 10th highest abundant endogenous gene. Only by aiming for coverage in the biofluid abundance 
range, one is able to assess the accuracy of biologically relevant differences. The results indicate how reliably 
fold changes can be detected using our total RNA seq method. Overall, there is a strong correlation between the 
expected and observed fold changes, with ERCC spikes (slope = 0.975, adjusted R2 = 0.67) behaving slightly bet-
ter than Sequin spikes (slope = 0.895, adjusted R2 = 0.78) since the slope is expected to be ‘1’ (Fig. 3B). Notably, 
larger variations arise when assessing smaller fold changes. Indeed, the lower the fold change, the bigger the 
spread in datapoints in the violin plot. We investigated this observation in more detail and found that deviation 
from the expected value is larger for spikes with fewer counts (Fig. 3C). In order to reliably measure small fold 
changes, it appears that a minimal number of 10 counts is advisable. Importantly, for about 90% of the spikes the 
deviation between the observed and expected log2 fold change is smaller than 0.5. This is shown in the cumulative 
distribution plot, where a minimum of 87.3% (for a log2 fold change difference of 1) and a maximum of 91.4% 
(for a difference of 2) of the spikes show a deviation from the expected value of maximum 0.5 (Fig. 3D). This 
indicates that the worst measurement for about 90% of the spikes is wrong with only a factor 1.41. What is more, 
almost all spikes can be measured within an error of a factor 2. In conclusion, although very small fold changes 
and fold changes of lower abundant transcripts are somewhat more difficult to detect, the method is reliable and 
approximates true fold changes very well.
The total RNA seq method is reproducible. As indicated above, technical replicates of the e PRP and 
ePFP samples were prepared at the level of RNA isolation. Scatter plots of the read counts clearly show that gene 
counts are reproducible between independent RNA extractions of the same plasma sample (Fig. 4). In addition, 
we generated cumulative distribution plots that display the fold change of every gene when comparing RNA 
isolation replicates (Fig. 5A). The area left of the curve (ALC) indicates the precision of the method, with lower 
values demonstrating better replication. Indeed, the more the curves are shifted to the left, the smaller the dif-
ferences between two replicates and thus the smaller the ALC value. In biological terms, this means that half of 
the genes can be detected with a fold change smaller than the ALC value. To illustrate, in ePRP of donor 2 half 
of the genes show a fold change less than 1.32 between both replicates (log2 fold change of 0.403, indicated in 
Fig. 5C). Cumulative distribution plots for the experiment with conditioned medium, citrate plasma, urine and 
their respective EVs (Fig. 5B). show slightly lower ALC values, indicating that reproducibility is better when rep-
lication is introduced at the level of library preparation (Fig. 5C).
Transcriptomes are widely different among tested biofluids. To assess the inherent variation of the 
various transcriptomes, we clustered all plasma, urine, conditioned medium and EV samples in a t-SNE plots 
(Sup Fig. 7). This plot confirms good reproducibility among technical replicates. Notably, EVs isolated from 
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Figure 4. RNA isolation replicates of ePRP and ePFP show high repeatability. A) ePRP and B) ePFP replicate 
correlation with filtered (counts <4, red) and retained genes (counts> = 4, green) resulted in high Pearson 
correlation of 0.912 and 0.948, respectively.
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healthy donor plasma and cancer cell conditioned medium seem to be quite similar. In contrast, urinary EVs do 
not cluster with these EVs, but show more similarity to whole urine. Next, when assessing the number of repro-
ducibly detected genes (mRNA, lncRNA, miscRNA pseudogenes and others), ePFP samples contain more genes 
compared to ePRP (Fig. 6A). This is probably due to lower amounts of (very abundant) mitochondrial RNA in 
ePFP, hence freeing up sequencing power to detect more genes. In addition, the 20 most abundant genes consume 
approximately 75% of the reads in ePRP, automatically leading to less diversity in the remaining gene fraction 
(Fig. 6B). The highest abundant genes in PRP are MTRNR2 (or paralogues), MTND1 and MTND2, which are all 
transcribed from mitochondrial DNA, as are many other genes in the top-20 (Sup Fig. 8). Urine and urinary EVs 
contain more than 10,000 genes in our experimental setup, the highest number of all evaluated biofluids (Fig. 6C). 
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Figure 6. The number of genes differs among sample types. A) Number of genes (counts> = 4) detected in 
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The lowest number of genes was observed in healthy donor citrate plasma derived EVs, in which only 904 genes 
could be detected using our total RNA seq method. Interesting to note is that plasma EVs had the worst mapping 
qualities of all samples (see Fig. 2A above). An important remark is that one should be cautious when interpreting 
the results above. Indeed, simply comparing gene numbers among different biofluids is difficult because of vary-
ing input volumes used for RNA purification. As already exemplified above, in the urine experiment we compare 
RNA extracted from 200 uL whole urine with RNA isolated from EVs that were present in 45 mL whole urine 
as starting material. To get further insights in the technical performance of the total RNA seq method, we also 
assessed the distribution of the counts (Sup Fig. 9) and the gene body coverage (Sup Fig. 10). In fragmented RNA, 
the coverage at the 5′ and 3′ end of the gene body is typically lower compared to the middle part.
We further investigated five different gene biotypes in all samples, according to their annotation in Ensembl 
(protein coding genes, lncRNA genes, miscellaneous RNA genes, pseudogenes and other genes). The percentage 
of counts assigned to these five gene types differs among the biofluids. ePRP for instance contains high number 
of pseudogene reads, resulting from mitochondrial genes as illustrated above, whereas ePFP mainly consists of 
reads mapping to protein coding genes (Fig. 7A). The differences in the other samples are less explicit. Looking 
into the top-20 genes with the highest counts reveals the genes consuming most of the reads in each sample (Sup 
Fig. 8). We also calculated the absolute numbers per gene biotype, but again we should keep in mind the difficulty 
in side-by-side comparisons because of differing input volumes (Fig. 7B,C). What we can conclude is that the 
method is able to pick up many different classes of RNA molecules.
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Figure 7. Detected gene-biotypes differ among sample types. A) Percentage of exonic reads attributed to 
the different biotypes per sample quantified with Kallisto. B-C) Detected number of genes per biotype for all 
samples.
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Next to Ensembl, we also assessed the reads mapping to LNCipedia11, the most comprehensive database of 
human long non-coding RNAs (Fig. 8A). In analogy with the results above, the largest number of lncRNAs was 
found in urine and urinary EVs. Indeed, approximately 3000 lncRNA genes can be distinguished associated with 
EVs isolated from urine. cPFP contains around 1500 lncRNAs, while we could detect almost no lncRNAs associ-
ated with EVs isolated from this plasma. As expected, ePFP contains more lncRNAs than ePRP. In addition, also 
the presence of circular RNAs was assessed. Their overall number is low, but especially cPFP and urinary EVs 
show substantially more circular RNAs (Fig. 8B). CircRNAs are presumed to be more stable and less degraded 
compared to linear forms. Therefore, they are ideal candidates for cancer biomarker discovery studies.
Evaluating biological differences in RNA content among biofluids. In order to illustrate which 
biological insights total RNA seq results can yield, we compared gene abundance in ePRP and ePFP samples (Sup 
Fig. 11). An Euler diagram indicates the number of genes that are unique to each plasma fraction, and the number 
of overlapping genes (Sup Fig. 11B). Studies like this (but with many more samples in each biofluid group) could 
lead to new insights into selective RNA cargo filling of extracellular vesicles. Here, we compared RNA abundance 
profiles between EVs and their biofluids of origin. Euler diagrams represent the number of overlapping and 
unique genes per pair of samples (Fig. 9A–C). Conditioned medium, for instance, shares 4891 genes (Jaccard 
index of 0.652) with the EVs it contains. Further, 1853 genes are only associated with EVs while 755 genes are 
unique to conditioned medium only. The results in plasma are markedly different: plasma EVs contain 1598 
genes, 70 of which are unique to EVs. RNA isolated from whole citrate plasma on the other hand contains 7211 
genes, nearly five times more, despite 30-fold lower input volume. Urine and urinary EVs finally have more than 
10,000 genes in common and contain 521 and 900 unique genes respectively. In addition, using scatter plots we 
represent the similarity between abundances for genes associated with EVs and their fluid of origin in another 
way (Fig. 9D,E). Supporting the results above, urine and urinary EVs have a great concordance in abundance of 
genes while citrate plasma and plasma EVs differ most from each other. Note that most of the EV-unique genes 
(indicated with dark blue dots) are low abundant. This could be due to chance (sampling effect) and sequencing 
deeper or using more input material may reduce this set of unique genes. In the same plot, we also indicated the 
count level of all genes uniquely present in one of both samples with colored lines. Notably, genes associated with 
EVs but absent from their biofluid of origin typically consume a lower number of counts. Digging deeper into 
biological analyses using bigger cohorts, from gene set enrichment to pathway analysis, may reveal novel insights. 
We validated the results by RT-qPCR for a set of genes abundant in all sample types (ACTB, EEF2 and TPT1), 
genes specific in conditioned medium (GPNMB, TPX2 and DKK1), genes specific in plasma (NRGN, PPBP and 
CAVIN2) and genes specific in urine (NEFH, NKX3 and TGM4) (Fig. 10).
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Figure 8. Non-coding RNAs, both linear and circular, are detected in total RNA sequencing libraries. A) 
Number of lncRNAs quantified based on LNCipedia. B) Number of circular RNAs detected with CircExplorer2.
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Discussion
Extracellular RNA content analysis of human biofluids and extracellular vesicles may provide insights into their 
biogenesis and reveal biomarkers for health and disease. There are currently four types of sequencing-based total 
RNA profiling of such challenging clinical samples: (1) the recent modified small RNA sequencing methods8,9,12, 
(2) the SOLiD total RNA sequening method13, (3) TGIRT-sequencing using thermostable group II intron reverse 
transcriptases5 and (4) SILVER-seq.14. The SMARTer method assessed in our study adds a fifth promising method 
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to the sequencing armory. In addition, the SMARTer method avoids limitations seen in other methods such as 
short fragments only, low number of quantified genes, high level of ribosomal RNA contamination, or lack of 
strandedness. Compared to most other existing technologies on biofluids, the SMARTer method is not purposed 
to quantify very short length RNA molecules such as microRNAs. A proper and extensive benchmarking study 
may be required to assess the relative merits and limitations of the various whole transcriptome profiling methods 
to study biofluid and EV associated RNA cargo.
While not marketed for this application, extensive technical performance assessment demonstrated that the 
SMARTer Stranded Total RNA-Seq method to be an accurate, precise and sensitive method to quantify total 
RNA in human biofluids. The tested biomaterials are purposely diverse and belong to donors with varying health 
status. Notable differences among plasma, urine, conditioned medium and their EVs could be related to the biol-
ogy of each fluid and should be taken into account when setting up biomarker studies. Possible improvements 
to profile platelet-rich plasma from EDTA tubes could be made by designing probes that remove mitochondrial 
ribosomal RNA, shown to be highly abundant (and unwanted) in this type of plasma. In this way, read diversity 
should increase and more genes at lower abundance will be identified. Quite striking was the observation that 
EVs from platelet-free citrate plasma contain substantially fewer genes. Whether the workflow can be optimized 
for plasma EVs definitely is a subject for further research. Besides, treatment of EVs with RNases to remove any 
non-encapsulated RNA may also prove useful15. We recommend, in concordance with the ISEV guidelines, to 
treat EV samples with an RNase if one is interested in RNA contained inside the vesicle.
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It has been shown that pre-analytical variables may have an effect on the resulting RNA profiles16. In our study, 
we also observed differences between ePFP and cPFP, which are identical biofluids collected in different blood 
tubes and prepared with a slightly different centrifugation protocol. In general, differences in pre-analytical var-
iables such as blood collection tubes, processing time, centrifugation speeds, RNA isolation kit, and freeze-thaw 
cycles could well be responsible for great variation in RNA sequencing results. Systematic evaluation of the 
impact of pre-analytical variables would definitely be of huge added value to progress the fields of extracellular 
RNA research and liquid biopsies. In order to obtain biologically meaningful results in future studies, uniform 
processing of all samples according to standard operating procedures will be of paramount importance.
In our study we included synthetic spike-in RNA mixes to control for variation during RNA isolation and/or 
library preparation. Of note, we did not include spikes during RNA isolation of EVs and their biofluids or origin 
because we did not include replicates at the RNA level. Ideally however, both Sequin spikes17 during RNA extrac-
tion and ERCC spikes before library preparation are added in all RNA sequencing experiments to control for 
different types of technical variation. As data interpretation is often complex in experiments involving different 
biofluids and input volumes, spike-in RNA could help with normalization, clarification and assimilation of raw 
data.
Finally, nuclear acids present in all sorts of biofluids and their EVs are promising biomarkers for diagnosis, 
prognosis, therapy response and monitoring of disease. The advantage of the SMARTer Stranded Total RNA-Seq 
method is its potential to process low amounts of input material. Indeed, collecting samples is often the bottleneck 
of fundamental, (pre)clinical and translational research projects and being able to disseminate large amounts of 
information from only 200 μL (or less) can substantially impact research progress.
Materials and Methods
Sample collection. ePRP and ePFP collection. For the first experiment, venous blood was drawn from an 
elbow vein of two healthy donors in 3 EDTA tubes (BD Vacutainer Hemogard Closure Plastic K2-Edta Tube, 
10 ml, #367525) using the BD Vacutainer Push blood collection set (21 G needle). Collection of blood samples 
was according to the Ethical Committee of Ghent University Hospital approval EC/2017/1207, following the 
ICH Good Clinical Practice rules, and written informed consents of all donors were obtained. The tubes were 
inverted 5 times and centrifuged within 15 minutes after blood draw (400 g, 20 minutes, room temperature, with-
out brake). Per donor, the upper plasma fractions were pipetted (leaving approximately 0.5 cm plasma above the 
buffy coat) and pooled in a 15 ml tube. After gently inverting, five aliquots of 220 µl platelet-rich plasma (ePRP) 
were snap-frozen in 1.5 ml LoBind tubes (Eppendorf Protein LoBind microcentrifuge tubes Z666548 - DNA/
RNA) in liquid nitrogen and stored at −80 °C. The remaining plasma was centrifuged (800 g, 10 minutes, room 
temperature, without brake) and transferred to a new 15 ml tube, leaving approximately 0.5 cm plasma above the 
separation. This plasma was centrifuged a 3rd time (2500 g, 15 minutes, room temperature, without brake), and 
transferred to a 15 ml tube, leaving approximately 0.5 cm above the separation. The resulting platelet-free plasma 
(ePFP) was gently inverted, snap-frozen in five aliquots of 220 µl and stored at −80 °C. The entire plasma prepa-
ration protocol was finished in less than two hours. 200 µl ePRP and ePFP was used for each RNA isolation. For 
the spike-in RNA titration experiment, the protocol was identical except for the fact that 4 EDTA tubes of 10 ml 
were drawn and that the second centrifugation step was different (1500 g, 15 minutes, room temperature, without 
brake).
cPFP collection and EV isolation. Venous blood was collected using a 21 G needle in 3.2% (w/v) sodium citrate 
tubes (MLS, Menen, Belgium) from an elbow vein of a healthy donor. Collection of blood samples was according 
to the Ethical Committee of Ghent University Hospital approval EC/2014/0655 following the ICH Good Clinical 
Practice rules. The participant had given written informed consent. Absence of hemolysis was confirmed by the 
lack of a spectrophotometric absorbance peak of free hemoglobin at 414 nm using a BioDrop DUO spectro-
photometer (BioDrop Ltd, Cambridge, United Kingdom). The blood tubes were inverted 5 times and plasma 
was prepared by centrifugation (2500 g with brake, 15 minutes, room temperature). The upper plasma fraction 
was collected (leaving approximately 0.5 cm plasma above the buffy coat layer) and transferred to a new 15 ml 
tube. Platelet-depleted plasma was prepared by centrifugation (2500 g with brake, 15 minutes, room temperature). 
Platelet-depleted plasma was collected (leaving approximately 0.5 cm plasma above the bottom of the tube), ali-
quoted per 1.5 ml in 2 ml cryo-vials and stored at −80 °C. To ensure the depletion of platelets in plasma we used 
the XP-300 Hematology Analyzer (Sysmex, Hoeilaart, Belgium). The blood sample was processed within 120 min 
after blood collection. 200 µl plasma was used for RNA isolation.
A combination of size exclusion chromatography (SEC) and OptiPrep density gradient (DG) centrifuga-
tion was used to isolate EV from plasma. Sepharose CL-2B (GE Healthcare, Uppsala, Sweden, #17014001) was 
washed 3 times with PBS (Merck Millipore, Billerica, Massachusetts, USA) containing 0.32% (w/v) trisodium-
citrate dihydrate (ChemCruz, Dallas, Texas, USA)18. For preparation of the SEC column, nylon filter with 20 µm 
pore size (Merck Millipore, Billerica, Massachusetts, USA) was placed on bottom of a 10 ml syringe (Romed, 
Wilnis, The Netherlands), followed by stacking of 10 ml Sepharose CL-2B. On top of three SEC columns, 6 ml 
plasma was loaded (2 ml per column) and fractions of 1 ml eluate were collected. SEC fractions 4, 5 and 6 were 
pooled and concentrated to 1 ml using 10 kDa centrifugal filter (Amicon Ultra-2ml, Merck Millipore, Billerica, 
Massachusetts, USA). The resulting 1 ml sample was loaded on top of a DG, as previously described19. This dis-
continuous iodixanol gradient was prepared by layering 4 ml of 40%, 4 ml of 20%, 4 ml of 10% and 3.5 ml of 5% 
iodixanol in a 17 ml Thinwall Polypropylene Tube (Beckman Coulter, Fullerton, California, USA). The DG was 
centrifuged 18 h at 100,000 g and 4 °C using SW 32.1 Ti rotor (Beckman Coulter, Fullerton, California, USA). 
Density fractions of 1 ml were collected and fractions 9–10 pooled. An additional SEC was performed on the 
pooled density fraction to remove iodixanol20. SEC fractions 4–7 were pooled and concentrated to 100 µl and 
stored at −80 °C until further use. Samples were further diluted to 200 µl in PBS prior to RNA isolation.
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Urine collection and EV isolation. One whole urine sample was collected from a prostate cancer patient prior to 
local treatment. Sample collection was according to the Ethical Committee of Ghent University Hospital approval 
EC/2015/0260 following the ICH Good Clinical Practice rules. The participant had given written informed con-
sent. The urine sample was collected immediately following digital rectal examination (DRE). DRE was per-
formed as 3 finger strokes per prostate lobe. The urine sample was centrifuged for 10 minutes at 1000 g and 
4 °C in accordance with the Eurokup/HKUPP Guidelines. Cell-free urine supernatants were collected (leaving 
approximately 0.5 cm urine above the cell pellet) and stored at −80 °C in 1.7 ml SafeSeal Microcentrifuge Tubes 
(Sorenson Bioscience) until further use. 200 µl urine was used for RNA isolation.
The cell-free urine sample (45 ml) was thawed at room temperature and vortexed extensively before being con-
centrated to 800 µl using a 10 kDa centrifugal filter device (Centricon Plus-70, Merck Millipore, Massachusetts, 
USA). The concentrated urine sample was resuspended in 3.2 ml of a 50% iodixanol solution and layered on the 
bottom of a 17 ml Thinwall Polypropylene Tube (Beckman Coulter, Fullerton, California, USA). A discontinuous 
DG was prepared by additional layering of 4 ml of 20%, 4 ml of 10% and 3.5 ml of 5% iodixanol, and 1 ml PBS on 
top of the urine suspension. The DG was centrifuged 18 h at 100,000 g and 4 °C using SW 32.1 Ti rotor (Beckman 
Coulter, Fullerton, California, USA). Density fractions of 1 ml were collected and fractions 9–10 pooled. An addi-
tional SEC was performed on the pooled density fraction to remove iodixanol. SEC fractions 4–7 were pooled 
and concentrated to 100 µl and stored at −80 °C until further use. Samples were further diluted in PBS to 200 µl 
for RNA isolation.
MCF-7 GFP-Rab27b conditioned medium and EV isolation. The MCF-7 cell line (ATCC, Manassas, VA, USA) 
was stably transfected with peGFP-C1 vector (Clontech, Mountain View, California, USA) containing the 
GFP-Rab27b fusion protein, as previously described (MCF-7 GFP-Rab27b)21. MCF-7 GFP-Rab27b cells were 
cultured in Dulbecco’s Modified Eagle Medium supplemented (DMEM) with 10% fetal bovine serum, 100 U/
ml penicillin, 100 µg/ml streptomycin and 1 mg/ml G418. Presence of mycoplasma was routinely tested using 
MycoAlert Mycoplasma Detection Kit (Lonza, Verviers, Belgium). To prepare conditioned medium (CM), 4 × 108 
MCF-7 GFP-Rab27b cells (20 × 175 cm2 flasks, 300 ml) were washed once with DMEM, followed by two washing 
steps with DMEM supplemented with 0.5% EV-depleted fetal bovine serum (EDS). EDS was obtained after 18 h 
ultracentrifugation at 100,000 g and 4 °C (SW55 Ti rotor, Beckman Coulter, Fullerton, California, USA), followed 
by 0.22 µm filtration. Flasks were incubated at 37 °C and 10% CO2 with DMEM containing 0.5% EDS. After 24 h, 
CM was collected and centrifuged for 10 min at 200 g and 4 °C. Cell counting was performed with trypan blue 
staining to assess cell viability (Cell Counter, Life Technologies, Carlsbad, California, USA). The supernatant was 
passed through a 0.45 µm cellulose acetate filter (Corning, New York, USA) and CM was concentrated to 1 ml at 
4 °C using a 10 kDa Centricon Plus-70 centrifugal unit (Merck Millipore, Billerica, Massachusetts, USA). 200 µl 
was used for RNA isolation. After filtering through a 0.22 µm filter (Whatman, Dassel, Germany), 1 ml concen-
trated conditioned medium (CCM) was used for DG ultracentrifugation. Fractions of 1 ml were collected and 
fractions 9–10 pooled. Pooled fractions were diluted to 15 ml with phosphate-buffered saline (PBS), followed 
by 3 h ultracentrifugation at 100,000 g and 4 °C using SW 32.1 Ti rotor (Beckman Coulter, Fullerton, California, 
USA). Resulting pellets were resuspended in 100 µl PBS and stored at −80 °C until further use. Samples were 
further diluted in PBS to 200 µl for RNA isolation.
Extracellular vesicle quality control. We have submitted all relevant data of our experiments to the 
EV-TRACK knowledgebase22 (EV-TRACK ID: EV190039).
Antibodies. The following antibodies were used for immunostaining: anti-Alix (1:1000, 2171 S, Cell Signaling 
Technology, Beverly, Massachusetts, USA), anti-TSG101 (1:1000, sc-7964, Santa Cruz Biotechnology, Dallas, 
Texas, USA), anti-CD9 (1:1000, D3H4P, Cell Signaling Technology, Beverly, Massachusetts, USA), anti-THP 
(1:800, sc-20631, Santa Cruz Biotechnology, Dallas, Texas, USA), anti-Flot-1 (1:1000, 610820, BD Biosciences, 
Franklin Lakes, New Jersey, USA), anti-Ago2 (1:1000, ab32381, Abcam, Cambridge, UK), anti-ApoA-1 (1:100, 
B10, Santa Cruz Biotechnology, Dallas, Texas, USA), sheep anti-mouse horseradish peroxidase-linked anti-
body (1:3000, NA931V, GE Healthcare Life Sciences, Uppsala, Sweden), donkey anti-rabbit horseradish 
peroxidase-linked antibody (1:4000, NA934V, GE Healthcare Life Sciences, Uppsala, Sweden).
Protein analysis. EV protein concentrations were measured using the fluorometric Qubit Protein Assay 
(ThermoFisher, Waltham, Massachusetts, USA). Sample preparation was done by 1:1 dilution with SDS 0.4%. 
Protein measurements were performed using the Qubit Fluorometer 3.0 (ThermoFisher, Waltham, Massachusetts, 
USA) according to the manufacturer’s instructions.
ODG fractions were dissolved in reducing sample buffer (0.5 M Tris-HCl (pH 6.8), 40% glycerol, 9.2% SDS, 
3% 2-mercaptoethanol, 0.005% bromophenol blue) and boiled at 95 °C for 5 min. Proteins were separated by 
SDS-PAGE (SDS-polyacrylamide gel electrophoresis), transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, California, USA), blocked in 5% non-fat milk in PBS with 0.5% Tween-20 and immunostained. 
Chemiluminescence substrate (WesternBright Sirius, Advansta, Menlo Park, California, USA) was added and 
imaging was performed using the Proxima 2850 Imager (IsoGen Life Sciences, De Meern, The Netherlands).
Nanoparticle tracking analysis. EV samples were analyzed by Nanoparticle tracking analysis (NTA) using a 
NanoSight LM10 microscope (Malvern Instruments Ltd, Amesbury, UK) equipped with a 405 nm laser. For each 
sample, three 60 second videos were recorded at camera level 13. Temperature was monitored during recording. 
Recorded videos were analyzed at detection threshold 3 with NTA Software version 3.2 to determine the concen-
tration and size distribution of measured particles with corresponding standard error. For optimal measurements, 
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samples were diluted with PBS until particle concentration was within the optimal concentration range for par-
ticle analysis (3 × 108–1 × 109).
Transmission electron microscopy. EV samples were qualitatively and quantitatively analyzed with transmission 
electron microscopy (TEM). Samples were deposited on Formvar carbon-coated, glow discharged grids, stained 
with uranylacetate and embedded in methylcellulose/uranylacetate. These grids were examined using a Tecnai 
Spirit transmission electron microscope (FEI, Eindhoven, The Netherlands) and images were captured with a 
Quemasa charge-coupled device camera (Olympus Soft Imaging Solutions, Munster, Germany).
RNA isolation, spike-in RNA addition and DNase treatment. RNA isolation was performed using 
the miRNeasy Serum/Plasma Kit (Qiagen). In experiment 1, ePRP and ePFP RNA was isolated from 200 µl of 
platelet-rich and platelet-free plasma from two healthy donors. Two RNA replicates were included. 2 µl of Sequin 
RNA spikes17 were added to the lysate at a dilution of 1/3000 for PFP and 1/250 for PRP, to control for variation in 
RNA isolation. After isolation, 2 µl of ERCC RNA spikes (ThermoFisher) were added to the eluate at a dilution of 
1/25 000 for PFP and 1/5000 for PRP. This allows to estimate the relative concentration of the eluate. For the ePFP 
RNA of the healthy donor, used for the spike-in RNA titration experiment (see 4.4), we used 6 aliquots of 200 µl 
plasma and pooled the RNA after isolation. We did not add Sequin spikes during RNA isolation. ERCC spikes 
were added following a titration series, as described in the next paragraph. Finally, RNA from EVs and their 
respective biofluids was isolated with the same kit, using 200 µl sample input (see also 4.1). No duplicates were 
included at the level of RNA isolation, no Sequin spikes were added, and the standard spin columns were replaced 
by Ultra-Clean Production (UCP) columns (Qiagen). ERCC spikes were added to the RNA isolation eluate at a 
dilution of 1/30 000 for plasma and urine and 1/50 for conditioned medium.
Spike-in RNA titration for assessment of trueness. Pooled ePFP RNA (prepared without Sequin 
spike-in RNA addition) was distributed in five separate tubes, each containing 12 µl RNA. Then, we added 1 µl 
DNase, 1.6 µl reaction buffer, 2 µl Sequin spikes and 2 µl ERCC spikes to each tube. Both spike-in RNA types 
were added in a 5-point 1.414-fold dilution series, in opposing order. For Sequin: 1/15,000, 1/21,277, 1/30,000, 
1/42,433 and 1/60,000. For ERCC: 1/100,000, 1/70,721, 1/50,000, 1/35,461 and 1/25,000.
Total RNA library preparation and sequencing. On the total amount of 12 µl eluate, gDNA 
heat-and-run removal was performed by adding 1 µl of HL-dsDNase (ArcticZymes 70800-202, 2 U/µl) and 1 µl 
reaction buffer (ArcticZymes 66001). Of the resulting volume, 4 µl was used as input for the total RNA library 
preparation protocol. Sequencing libraries were generated using SMARTer Stranded Total RNA-Seq Kit v2 - Pico 
Input Mammalian (Takara, 634413). Compared to the manufacturer’s protocol, the fragmentation step was set 
to 4 min at 94 °C, hereafter the option to start from highly degraded RNA was followed. Library quality control 
was performed with the Fragment Analyzer high sense small fragment kit (Agilent Technologies, sizing range 50 
bp-1000 bp). Based on Qubit concentration measurements or KAPA qPCR, samples were pooled and loaded on 
the NextSeq. 500 (Illumina) with a loading concentration of 1.1 or 1.2 pM. Note that the 1.2 pM resulted in lower 
quality reads as the run was slightly overloaded. Paired end sequencing was performed (2 × 75 bp) with median 
depth of 15.3 million reads per sample. The fastq data is deposited in GEO (GSE131689).
RT-qPCR validation. For the validation of 12 selected genes by RT-qPCR, assays were carefully designed 
using primerXL23 (www.primerxl.org) and efficiencies tested using a 6-point 10-fold synthetic template dilution 
series from 1,000,000 down to 10 molecules. For cDNA synthesis, the iScript cDNA Synthesis Kit (Bio-Rad) was 
used according to the manufacturer; 2 µl of input RNA was added to 1 µl of enzyme, 4 µl of 5x reaction mix, and 
13 µl of nuclease free water. The samples were incubated for 30 minutes at 42 °C and 5 min at 85 °C. Subsequently, 
cDNA was diluted by adding 60 µl nuclease free water. RT-qPCR was performed in a 5 µl reaction in duplicate 
in 384-multiwell plates (Bio-Rad) using 2.5 µl 2x SsoAdvanced SYBR Green Supermix (Bio-Rad), 0.25 µl of each 
primer (5 µM) and 2 µl cDNA. The thermal cycling protocol comprises a polymerase activation step at 95 °C for 
30 seconds, followed by 40 cycles of denaturation at 98 °C for 15 seconds, annealing/extension and read out at 
60 °C and ends with melt curve analysis during 5 second 0.5 °C increment steps from 65 °C to 95 °C on a CFX384 
(Bio-Rad). Cq values were exported from the CFX Manager software and imported in qbase + v3.124 (www.qbase-
plus.com) for data-analysis using multigene normalization (ACTB, EEF2, TPT1), error propagation, and rescal-
ing to the sample with the highest abundance.
Sequencing data quality control. The reads with a low quality score (Q30) were discarded, hereafter 
read duplicates were removed with Clumpify (BBMap v.37.93, standard settings). The libraries were trimmed 
using cutadapt (v.1.16)25 to remove 3 nucleotides of the 5′ end of read 2. To enable a fair comparison, we started 
data-analysis from an equal number of reads by subsampling to 1 million trimmed and deduplicated reads. To 
assess the quality of the data, the reads were mapped using STAR (v.2.6.0)26 on the hg38 genome including the 
spikes, full ribosomal DNA (45 S, 5.8 S and 5 S) and mitochondrial DNA sequences. The parameters of STAR 
were according to the ENCODE project (–twopassMode Basic–outSAMmultNmax 20–outSAMprimaryFlag 
AllBestScore–outFilterMismatchNmax 999–outFilterMismatchNoverReadLmax 0.04–alignIntronMin 20–
alignIntronMax 1000000–alignMatesGapMax 1000000). Using SAMtools (v1.6)27,reads mapping to the different 
nuclear chromosomes, mitochondrial DNA and rRNA were extracted and annotated as exonic, intronic or inter-
genic. The SMARTer total RNA sequencing data is stranded and processed accordingly, so strandedness was con-
sidered for each analysis step. Gene body coverage was calculated using the full Ensembl (v91)28 transcriptome. 
The coverage per percentile was calculated.
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Quantification of Ensembl and LNCipedia genes, differential abundance analysis and gene set 
enrichment analysis. Genes were quantified by Kallisto (v.0.43.1)29 using both Ensembl (v.91)28 extended 
with the ERCC spike and Sequin spike sequences and LNCipedia (v.5.0)11. The strandedness of the total RNA-seq 
reads was considered by running the –rf-stranded mode. Further processing was done with R (v.3.5.1) making 
use of tidyverse (v.1.2.1). A cut-off for filtering noisy genes was set based on an analysis of single positive and 
double positive genes. For a cut-off of 4 counts, at least 95% of the single positive values are filtered out. To meas-
ure the biological signal, we first performed differential expression analysis between the treatment groups using 
DESeq. 2 (v.1.20.0)30. To identify enriched gene sets a fsgea (v.1.6.0) analysis was performed, calculating enrich-
ment for the gene sets retrieved from MSigDB (v.6.2).
Circular RNA detection. CircRNAs were annotated by using the combination of STAR (v.2.6.0)26 and 
CIRCexplorer2 (v2.3.3)31. The settings of STAR (used according to Vo et al.) are slightly different compared to 
linear mapping4. Human genome hg38 was used for circRNA analysis. CircRNAs were annotated with host gene 
names from RefSeq.
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